Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imatinib Teva

- PMLiVE

The sound of silence puts the squeeze on generics and biosimilars

Medicines for Europe vows to get  governments talking to realise potential

- PMLiVE

Novartis appoints Shaun Coughlin to lead its US biomedical research institute

The renowned academic joins as the pharma firm's global head of cardiovascular and metabolism

- PMLiVE

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

- PMLiVE

Biocon backs away from biosimilar filings in Europe

EMA asks biotech to withdraw Herceptin and Neulasta biosimilar filings

Biosimilars: Getting the flock to market

The biosimilars field is about to become very crowded. Here are some Life tips on how to stand out from the herd

Life Healthcare Communications

- PMLiVE

Teva to cut 7000 jobs, close 15 manufacturing sites

Missed second-quarter sales expectations prompt the cutbacks

- PMLiVE

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

- PMLiVE

Merck & Co’s Remicade biosimilar undercuts its US rivals

Its version will be 35% cheaper than J&J's originator product

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links